FDA Approved Breast Cancer DNA Test by 23andMe May do More Harm than Good
By Joyce Bichler,
Breast Cancer Action
| 03. 07. 2018
Yesterday, the Food and Drug Administration (FDA) for the first time approved an at-home genetic testing kit without a doctor’s prescription to predict the risk of breast cancer. While there’s no doubt the move will be celebrated by some, the truth is that there is cause for serious concern. This decision by the FDA threatens to do more harm than good for women at risk of and living with breast cancer.
Most immediately, the 23andMe test approved for over-the-counter use looks at just three of the more than 1000 known BRCA1 and BRCA2 mutations. While these three specific mutations are the most common BRCA1 and BRCA2 mutations for people of Ashkenazi ancestry, they are not the most common BRCA mutations in the broader population, raising serious health equity concerns. This means that if you’re someone who receives a negative result from the 23andMe test, there is still the possibility that you may carry other harmful BRCA mutations that increase the risk of breast cancer.
At Breast Cancer Action, we’ve long argued that genetic testing should always be accompanied by independent...
Related Articles
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...
By Carl Zimmer, The New York Times | 05.31.2024
Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not...
By Liz Szabo, The New York Times | 05.29.2024
By the time Rena Barrow-Wells gave birth to her fourth baby in 2020, she was well-versed in caring for a child with cystic fibrosis. She was also experienced in fighting for a diagnosis of the disease, which runs in families...
By Alison Snyder, Axios | 06.06.2024
Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: ...